How should I differentiate lupus nephritis from other glomerulonephritis and what are the recommended treatment strategies?

Differentiating Lupus Nephritis from Other Glomerulonephritis

Lupus nephritis is distinguished from other glomerulonephritis primarily through kidney biopsy showing characteristic immunofluorescence patterns ("full house" staining with IgG, IgA, IgM, C3, and C1q) combined with serologic evidence of SLE, while treatment requires continuous multi-agent immunosuppression with glucocorticoids plus mycophenolate mofetil or cyclophosphamide as first-line therapy. 1

Diagnostic Differentiation

Clinical Context

• LN develops in 25-60% of SLE patients, typically within 5 years of diagnosis, though it can present as the initial SLE manifestation or develop late in the disease course 2
• Screen for proteinuria, microhematuria, and renal dysfunction at SLE diagnosis and during all subsequent follow-ups 3

Serologic Markers

• Positive ANA, anti-dsDNA antibodies, and low complement levels (C3/C4) support LN diagnosis 2
• The presence of anti-dsDNA and hypocomplementemia helps distinguish active LN from other forms of glomerulonephritis 3

Kidney Biopsy - The Gold Standard

• Perform kidney biopsy when significant proteinuria, microhematuria, or renal dysfunction develops, as histopathology directly impacts therapeutic choices 3
• LN shows characteristic "full house" immunofluorescence pattern with deposition of multiple immunoglobulins (IgG, IgA, IgM) and complement components (C3, C1q) 1
• Classify according to ISN/RPS system: Classes III and IV (proliferative GN) carry the worst prognosis and require aggressive treatment 1, 4
• Residual immune deposits (beyond IgM and C3) in globally sclerotic glomeruli indicate lupus-related injury rather than other causes 1

Histopathologic Pitfalls

• Distinguish lupus-related global sclerosis from arterionephrosclerosis: subcapsular clusters with ischemic collapse suggest non-lupus injury 1
• Segmental sclerosis from active LN shows features like fragmented tuft with fibrosis and disrupted Bowman's capsule, differentiating it from post-adaptive changes 1

Treatment Strategies

Initial/Induction Therapy for Proliferative LN (Class III/IV)

First-Line Options:

• Glucocorticoids combined with either MMF or cyclophosphamide are the standard initial treatments 1, 5
• Pulse methylprednisolone followed by oral prednisone taper to ≤5 mg/day 1, 6
• Consider upfront triple therapy (glucocorticoids + two immunosuppressive agents) in patients at high risk of progression 6

Specific Regimens:

• MMF has emerged as first-line therapy with similar efficacy to cyclophosphamide but better tolerability 4, 3
• Cyclophosphamide reserved for severe presentations: crescentic GN with rapidly declining function, significant baseline renal impairment, or refractory disease 4
• Calcineurin inhibitors (tacrolimus, voclosporin) are alternatives, with voclosporin showing sustained proteinuria reduction (median time to proteinuria <0.5 mg/mg was 3.6 months) 1

Maintenance/Subsequent Therapy

Duration and Agents:

• Continue therapy for at least 3-5 years in patients achieving complete renal response to reduce flare risk 5, 6
• MMF or azathioprine are maintenance options, but MMF maintenance should follow MMF induction 1, 6
• If MMF and azathioprine cannot be used, consider CNIs, mizoribine, or leflunomide (though leflunomide requires 2-year discontinuation before conception) 1
• Maintain prednisone at ≤5 mg/day during maintenance 6

Class V (Membranous) LN

Proteinuria-Guided Approach:

• Low-level proteinuria: RAS blockade, blood pressure control, hydroxychloroquine; immunosuppression guided by extrarenal SLE manifestations 1
• Nephrotic-range proteinuria: Combined immunosuppressive therapy (glucocorticoid + MMF/cyclophosphamide/CNI) plus RAS blockade and hydroxychloroquine 1
• Unlike primary membranous nephropathy, heavy proteinuria in Class V LN rarely remits spontaneously 1
• Triple immunosuppression (glucocorticoids + tacrolimus + low-dose MMF) showed higher complete remission rates (33.1% vs 7.8%) compared to cyclophosphamide followed by azathioprine 1

Treatment Monitoring and Response

Target Outcomes:

• Aim for rapid and complete remission: tight proteinuria control is increasingly emphasized 7, 8
• Complete renal response, partial renal response, and ≥50% reduction in urine protein-creatinine ratio are key endpoints 9
• For refractory disease, consider switching or adding biological agents (rituximab, belimumab) or alternative immunosuppressives 4, 6

Adjunctive Therapies

Universal Recommendations:

• Hydroxychloroquine for all LN patients unless contraindicated 1, 5
• RAS blockade (ACE inhibitors/ARBs) for blood pressure control and proteinuria reduction 1, 4
• Manage cardiovascular risk factors aggressively: dyslipidemia, hypertension, thrombosis prophylaxis 4, 3
• Monitor and treat complications: infections, osteoporosis, metabolic abnormalities 4, 6

Key Clinical Pitfalls

• Do not delay biopsy: histologic classification is essential for appropriate treatment selection 3
• Avoid prolonged high-dose glucocorticoids: taper rapidly to minimize toxicity while maintaining disease control 7, 5
• Recognize that LN therapy is continuous, not discrete induction/maintenance phases: treatment should be ongoing for years 5
• Monitor for disease flares during maintenance: persistent proteinuria, low GFR, and hypertension predict progression to kidney failure 2